{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:15:27Z","timestamp":1748405727756,"version":"3.41.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To compare intravitreal aflibercept alone versus aflibercept combined with oral anti-inflammatory supplementation in patients with diabetic macular edema.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A prospective, randomized study included 134 treatment-naive eyes with central-involving diabetic macular edema. Participants were assigned to receive either intravitreal aflibercept (Group A) or aflibercept with oral Lenidase supplementation (Group B, containing baicalin, bromelain, and escin). Both groups followed a treat-and-extend regimen. The primary outcome was the number of injections over 24 months. Secondary outcomes included changes in best-corrected visual acuity, central macular thickness, and safety assessments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At 24 months, Group A required a mean of 14.34 \u00b1 0.51 injections, while Group B required 12.96 \u00b1 0.44 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). Both groups showed significant improvement in best-corrected visual acuity: from 0.62 \u00b1 0.12 logMAR (20\/83 Snellen) to 0.43 \u00b1 0.13 logMAR (20\/54 Snellen) in Group A and from 0.64 \u00b1 0.13 logMAR (20\/87 Snellen) to 0.42 \u00b1 0.15 logMAR (20\/53 Snellen) in Group B (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001 for both). Central macular thickness also significantly decreased in both groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). No significant differences were found between the groups for vision improvement (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.918) or central macular thickness reduction (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.777). No ocular complications were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Oral supplementation with Lenidase showed similar efficacy to aflibercept monotherapy in diabetic macular edema, with fewer injections, potentially reducing treatment burden.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004427","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T22:00:44Z","timestamp":1740088844000},"page":"1134-1142","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["COMBINED INTRAVITREAL AFLIBERCEPT AND ANTI-INFLAMMATORY ORAL SUPPLEMENTATION IN THE TREATMENT OF DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-0926","authenticated-orcid":false,"given":"Paola","family":"Marolo","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Li","family":"Volti","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, Section of Biochemistry, University of Catania, Catania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Nicolosi","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit, Ospedale Cannizzaro, Catania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresio","family":"Avitabile","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fallico","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guglielmo","family":"Parisi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Damiano","family":"Toro","sequence":"additional","affiliation":[{"name":"Department of General Ophthalmology, Medical University of Lublin, Lublin, Poland;"},{"name":"Eye Clinic, Public Health Department, Federico II University, Naples, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"de Sanctis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Motta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Padova, Padua, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2021.09.002","article-title":"Long-term visual outcomes and morphologic biomarkers of vision loss in eyes with diabetic macular edema treated with anti-VEGF therapy","volume":"235","author":"Borrelli","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","article-title":"Mechanisms of macular edema: beyond the surface","volume":"63","author":"Daruich","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2018.03.007","article-title":"Effects of crocin on diabetic maculopathy: a placebo-controlled randomized clinical trial","volume":"190","author":"Sepahi","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/IAE.0000000000002114","article-title":"THREE-YEAR outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema","volume":"39","author":"Lafuente","year":"2019","journal-title":"Retina"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"13","DOI":"10.23736\/S2724-6507.23.04080-0","article-title":"Antioxidants for male infertility: therapeutic scheme and indications. A retrospective single-center real-life study","volume":"49","author":"Cannarella","year":"2024","journal-title":"Minerva Endocrinol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4081\/aiua.2013.2.65","article-title":"Does prolonged anti-inflammatory therapy reduce number of unnecessary repeat saturation prostate biopsy?","volume":"85","author":"Candiano","year":"2013","journal-title":"Archivio italiano di urologia, andrologia: organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.oret.2021.12.019","article-title":"Frequency of intravitreal anti-VEGF injections and risk of death: a systematic review with meta-analysis","volume":"6","author":"Reibaldi","year":"2022","journal-title":"Ophthalmol Retin"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.ophtha.2011.09.058","article-title":"Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema","volume":"118","author":"Aiello","year":"2011","journal-title":"Ophthalmology"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archopht.1993.01090060119035","article-title":"The lens opacities classification system III. The longitudinal study of cataract study group","volume":"111","author":"Chylack","year":"1993","journal-title":"Arch Ophthalmol (Chicago, IL 1960)"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1167\/iovs.11-8755","article-title":"Signal quality assessment of retinal optical coherence tomography images","volume":"53","author":"Huang","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/tvst.10.2.39","article-title":"Association of macular thickness with age and age-related macular degeneration in the carotenoids in age-related eye disease study 2 (CAREDS2), an ancillary study of the women's health initiative","volume":"10","author":"Etheridge","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaophthalmol.2021.0146","article-title":"A global assessment of eye health and quality of life: a systematic review of systematic reviews","volume":"139","author":"Assi","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","article-title":"Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study","volume":"100","author":"Pr\u00fcnte","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2019.02.005","article-title":"Randomized trial of treat and extend ranibizumab with and without navigated laser versus monthly dosing for diabetic macular edema: TREX-DME 2-year outcomes","volume":"202","author":"Payne","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1039\/D3FO01060K","article-title":"Bromelain: a review of its mechanisms, pharmacological effects and potential applications","volume":"14","author":"Kumar","year":"2023","journal-title":"Food Funct"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14786419.2024.2342553","article-title":"Bromelain as a natural anti-inflammatory drug: a systematic review","volume":"39","author":"Alves Nobre","year":"2025","journal-title":"Nat Prod Res"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/02601060231173732","article-title":"Efficacy and safety of bromelain: a systematic review and meta-analysis","volume":"29","author":"Leelakanok","year":"2023","journal-title":"Nutr Health"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:48:18Z","timestamp":1748357298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004427"}},"subtitle":["Two-Year Randomized Controlled Trial Results"],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004427","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"type":"print","value":"0275-004X"},{"type":"electronic","value":"1539-2864"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}